Subscribe to European Biotechnology Magazine’s news feed.
Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: European Biotechnology Magazine
Is this your feed? Claim it!
Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the 251-patient Phase 2 ASTRALS trial missed its primary and secondary endpoints, and shortly after Axoltis Pharma suffered a similar Phase 2 setback.
The post
Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
The post
Novo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
The post
Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
The post Roche taps Dualitas in...
As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
The post